Stem Cells for Safer Medicines, a UK public-private partnership that is developing stem cell technology for drug research, has appointed Frank Bonner as its new chief executive. He will replace Philip Wright, who is the partnership’s first executive. Professor Bonner is a visiting professor at the Institute of Cellular Medicine at Newcastle University, UK and an independent consultant in toxicology and non-clinical drug safety assessment. He is a member of the scientific advisory boards of several companies, having spent more than 25 years in the pharmaceutical and contract research industries.
Professor Bonner obtained a BSc degree in biochemistry and a PhD in toxicology from the University of Surrey in Guildford, UK.
Copyright 2009 Evernow Publishing Ltd